Rare malignant ovarian tumors: a review.

IF 2.2 4区 医学 Q3 ONCOLOGY Japanese journal of clinical oncology Pub Date : 2025-03-05 DOI:10.1093/jjco/hyaf005
Mitsuya Ishikawa
{"title":"Rare malignant ovarian tumors: a review.","authors":"Mitsuya Ishikawa","doi":"10.1093/jjco/hyaf005","DOIUrl":null,"url":null,"abstract":"<p><p>There are many histologic types of gynecologic malignancies. I reviewed three rare ovarian tumor types that have poor prognoses. Ovarian mesonephric-like adenocarcinoma (MLA) is a newly described histological type known for its aggressive behavior. It is thought to arise from mesonephric duct remnants of the female genital tract and is typically associated with endometriosis. Although MLA has some similarities to endometrioid carcinoma, they have different prognoses. Recurrence of MLA is common, even in early stage cases, and distant metastases, especially in the lungs, are often seen. MLA is characterized by positive immunohistochemical-staining for TTF-1, GATA3, PAX2, and CD10, and negative staining for estrogen and progesterone receptors. Data on treatment for MLA are scarce, and further studies are needed. Adult granulosa cell tumors, the most common type of malignant ovarian sex cord-stromal tumors, have an indolent growth pattern. Chemotherapy, hormone therapy, and radiotherapy have all shown some efficacy. However, debulking surgery remains the most important treatment because tumor disruption or remnants are risk factors for recurrence. Late recurrence is also characteristic of this tumor. Malignant transformations of mature teratoma are suspected when the patient is relatively old and the tumor is large. Squamous cell carcinoma is the most common somatic malignancy. Treatment must be tailored to the transformed histology. Chemotherapy and radiation have shown some efficacy; however, the prognosis is extremely poor in advanced cases. Because these three types of ovarian tumors are rare, research on possible treatments has been difficult, but recent significant advances in drug therapy are expected to lead to the development of effective treatments.</p>","PeriodicalId":14656,"journal":{"name":"Japanese journal of clinical oncology","volume":" ","pages":"205-209"},"PeriodicalIF":2.2000,"publicationDate":"2025-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Japanese journal of clinical oncology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1093/jjco/hyaf005","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

There are many histologic types of gynecologic malignancies. I reviewed three rare ovarian tumor types that have poor prognoses. Ovarian mesonephric-like adenocarcinoma (MLA) is a newly described histological type known for its aggressive behavior. It is thought to arise from mesonephric duct remnants of the female genital tract and is typically associated with endometriosis. Although MLA has some similarities to endometrioid carcinoma, they have different prognoses. Recurrence of MLA is common, even in early stage cases, and distant metastases, especially in the lungs, are often seen. MLA is characterized by positive immunohistochemical-staining for TTF-1, GATA3, PAX2, and CD10, and negative staining for estrogen and progesterone receptors. Data on treatment for MLA are scarce, and further studies are needed. Adult granulosa cell tumors, the most common type of malignant ovarian sex cord-stromal tumors, have an indolent growth pattern. Chemotherapy, hormone therapy, and radiotherapy have all shown some efficacy. However, debulking surgery remains the most important treatment because tumor disruption or remnants are risk factors for recurrence. Late recurrence is also characteristic of this tumor. Malignant transformations of mature teratoma are suspected when the patient is relatively old and the tumor is large. Squamous cell carcinoma is the most common somatic malignancy. Treatment must be tailored to the transformed histology. Chemotherapy and radiation have shown some efficacy; however, the prognosis is extremely poor in advanced cases. Because these three types of ovarian tumors are rare, research on possible treatments has been difficult, but recent significant advances in drug therapy are expected to lead to the development of effective treatments.

查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
罕见恶性卵巢肿瘤的研究进展。
妇科恶性肿瘤有多种组织学类型。我回顾了三种预后不良的罕见卵巢肿瘤类型。卵巢中肾样腺癌(MLA)是一种以其侵袭性行为而闻名的新描述的组织学类型。它被认为是由女性生殖道的中肾管残余引起的,通常与子宫内膜异位症有关。虽然MLA与子宫内膜样癌有一些相似之处,但它们的预后不同。MLA的复发是常见的,即使在早期病例,远处转移,特别是在肺部,是经常看到的。MLA的特征是TTF-1、GATA3、PAX2和CD10免疫组化染色阳性,雌激素和孕激素受体免疫组化染色阴性。关于MLA治疗的数据很少,需要进一步研究。成人颗粒细胞瘤是卵巢性索间质恶性肿瘤中最常见的一种,生长缓慢。化疗、激素治疗和放射治疗都显示出一定的疗效。然而,减体积手术仍然是最重要的治疗方法,因为肿瘤破裂或残留是复发的危险因素。晚期复发也是该肿瘤的特点。当患者年龄较大,肿瘤较大时,可怀疑成熟畸胎瘤的恶性转化。鳞状细胞癌是最常见的躯体恶性肿瘤。治疗必须根据转变后的组织学进行调整。化疗和放疗已显示出一定的疗效;然而,晚期患者预后极差。由于这三种类型的卵巢肿瘤是罕见的,研究可能的治疗方法一直很困难,但最近在药物治疗方面的重大进展有望导致有效治疗的发展。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
CiteScore
3.70
自引率
8.30%
发文量
177
审稿时长
3-8 weeks
期刊介绍: Japanese Journal of Clinical Oncology is a multidisciplinary journal for clinical oncologists which strives to publish high quality manuscripts addressing medical oncology, clinical trials, radiology, surgery, basic research, and palliative care. The journal aims to contribute to the world"s scientific community with special attention to the area of clinical oncology and the Asian region. JJCO publishes various articles types including: ・Original Articles ・Case Reports ・Clinical Trial Notes ・Cancer Genetics Reports ・Epidemiology Notes ・Technical Notes ・Short Communications ・Letters to the Editors ・Solicited Reviews
期刊最新文献
Contrasting responses to neoadjuvant immunotherapy in synchronous transverse colon cancers with discordant mismatch repair status. Resolution of peritoneal metastases in CLDN18.2-positive gastric cancer treated with CAPOX plus zolbetuximab. Author's reply to 'Trends in Usage and Drug Costs of Immune-Checkpoint Inhibitors in Japan'. Sacituzumab govitecan in Japanese participants with HR+/HER2- metastatic breast cancer: primary results from the phase II ASCENT-J02 study. The letter to editor regarding 'Trends in Usage and Drug Costs of Immune Checkpoint Inhibitors in Japan'.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1